Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: A randomized, double‐blind, controlled trial
Open Access
- 30 August 2011
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 63 (12) , 1654-1663
Abstract
Objective: To define the effects of continuous sequential estrogen plus progestin therapy on menopausal symptoms in women with systemic lupus erythematosus (SLE).Methods: We performed a randomized, double‐blind, 24‐month clinical trial involving 106 women with SLE who were in the menopausal transition or early or late postmenopause. Patients received continuous sequential estrogen plus progestin (n = 52) or placebo (n = 54). Menopausal symptoms were assessed using the Greene Climacteric Scale at 0, 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months. A new factor analysis of the scale reduced 21 items to 5 factors. The primary outcome was improvement of menopausal symptoms throughout the followup period. Results were analyzed by the intent‐to‐treat principle.Results: At baseline, demographic and disease characteristics were similar in both groups. Fifteen of 21 menopausal symptoms had a prevalence of ≥50%, with a similar distribution between groups. Vasomotor factor scores decreased over time in both groups (P = 0.002), but in the estrogen plus progestin group the reduction was more pronounced than in the placebo group (1.5–2.0 versus 0.35–0.8 points on a scale of 0–6; P = 0.03). Maximum effects were observed among the most symptomatic women. Psychological, subjective–somatic, and organic–somatic factors scores also improved along time (P < 0.001), but the treatment and placebo arms improved to a similar degree. Thromboses occurred in 3 patients receiving estrogen plus progestin and in 1 patient receiving placebo.Conclusion: Menopausal symptoms are highly prevalent in peri‐ and postmenopausal lupus patients. Estrogen plus progestin improved vasomotor symptoms at a clinically significant level, but not other menopausal symptoms. Given the thrombotic risks of menopausal hormone therapy, this should be used only in women with significant vasomotor symptoms.Keywords
This publication has 36 references indexed in Scilit:
- Estrogen and progestogen use in postmenopausal womenMenopause, 2010
- Approach to the Patient with Menopausal SymptomsThe Journal of Clinical Endocrinology & Metabolism, 2008
- Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus ErythematosusThe Journal of Rheumatology, 2008
- Menopause hormonal therapy in women with systemic lupus erythematosusArthritis & Rheumatism, 2007
- IMS Updated Recommendations on postmenopausal hormone therapyClimacteric, 2007
- Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001Menopause, 2001
- Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.Annals of the Rheumatic Diseases, 1996
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- Autoimmune Etiology in Premature Ovarian FailureAmerican Journal of Reproductive Immunology, 1988
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982